LEADER 00880nam0-22002651i-450 001 990005053160403321 005 20230301114235.0 035 $a000505316 035 $aFED01000505316 035 $a(Aleph)000505316FED01 100 $a19990530g19219999km-y0itay50------ba 101 0 $afre 105 $af-------001yy 200 1 $a<>manuscrit de Bayeux$eTexte et musique d'un recueil de chansons du XV siècle$fprèsenté par Théodore Gérold 210 $aStrasbourg,Paris$cen depot a la Libr. Istra$d1921 215 $aLIV, 127 p.$ctav.$d25 cm 225 1 $aPublications de la Faculté des Lettres de l'Université de Strasbourg$v2 702 1$aGérold,$bThéodore 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990005053160403321 952 $aMX CH 12$bFil.Mod. 269$fFLFBC 959 $aFLFBC 996 $aMANUSCRIT de Bayeux$9532831 997 $aUNINA LEADER 02373nam 2200409z- 450 001 9910220059703321 005 20210211 035 $a(CKB)3800000000216181 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/50258 035 $a(oapen)doab50258 035 $a(EXLCZ)993800000000216181 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aInhibiting PARP as a Strategic Target in Cancer 210 $cFrontiers Media SA$d2016 215 $a1 online resource (97 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-955-X 330 $aPoly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell's ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage. 606 $aMedicine$2bicssc 610 $aCancer 610 $acombination therapy 610 $aDNA Damage 610 $aDNA reapir 610 $aHomologous Recombination 610 $aPARP inhibitor 615 7$aMedicine 700 $aKristin Zorn$4auth$01311554 702 $aChristina Annunziata$4auth 906 $aBOOK 912 $a9910220059703321 996 $aInhibiting PARP as a Strategic Target in Cancer$93030415 997 $aUNINA